157 related articles for article (PubMed ID: 36070113)
1. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Lum JHY; Nga ME; Goh GH; Seet JE; Chee CE; Tan HL; Ho J; Ngoi NYL; Lee MXW; Muthu V; Chan GHJ; Pang ASL; Ang YLE; Choo JRE; Lim JSJ; Teh JL; Lwin A; Soon Y; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2022 Dec; 29(13):8597-8605. PubMed ID: 36070113
[TBL] [Abstract][Full Text] [Related]
2. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Chan DY; Syn NL; Yap R; Phua JN; Soh TI; Chee CE; Nga ME; Shabbir A; So JB; Yong WP
J Gastrointest Surg; 2017 Mar; 21(3):425-433. PubMed ID: 27981493
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
4. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
Tu L; Zhang W; Ni L; Xu Z; Yang K; Gou H; Zhu Q; Liu M; Yang Y; Hu J; Qiu M
Cancer Med; 2023 Feb; 12(4):4161-4169. PubMed ID: 36161282
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
[TBL] [Abstract][Full Text] [Related]
7. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Mariani A; Zaanan A; Glehen O; Karoui M
Ann Surg Oncol; 2023 Feb; 30(2):816-817. PubMed ID: 36383333
[No Abstract] [Full Text] [Related]
9. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2023 Mar; 30(3):1889-1890. PubMed ID: 36564654
[No Abstract] [Full Text] [Related]
10. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Kang SH; Min SH; Kim JW; Lee E; Park SW; Lee S; Oh HJ; Park YS; Lee YJ; Kim JW; Ahn SH; Suh YS; Lee KW; Lee HS; Kim HH
Ann Surg Oncol; 2022 Aug; 29(8):5084-5091. PubMed ID: 35322307
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases.
Saito S; Yamaguchi H; Ohzawa H; Miyato H; Kanamaru R; Kurashina K; Hosoya Y; Lefor AK; Sata N; Kitayama J
Ann Surg Oncol; 2021 Jul; 28(7):3863-3870. PubMed ID: 33270170
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
Zhang X; Huang H; Yang D; Wang P; Huang X; Hu Z; Zhang Y; Yan R; Zhu Z; Cai Q
Technol Cancer Res Treat; 2021; 20():15330338211036310. PubMed ID: 34328799
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
14. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.
Yang Z; Lu S; Shi M; Yuan H; Wang Z; Ni Z; He C; Zheng Y; Zhu Z; Liu W; Yao X; Zhang J; Li C; Yan M; Yan C; Zhu Z
Gastric Cancer; 2024 Mar; 27(2):387-399. PubMed ID: 38143257
[TBL] [Abstract][Full Text] [Related]
15. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
